Oncolytic virus VG161 in refractory hepatocellular carcinoma

compartió un enlace

2025-03-20 13:16:38 - Traducir -

WWW.NATURE.COM

Nature, Published online: 19 March 2025; doi:10.1038/s41586-025-08717-5Results of a multicentre phase 1 clinical trial evaluating treatment with the engineered herpes simplex virus VG161 in advanced liver cancer indicate a good safety profile and promising efficacy.

0 Comentarios 0 Compartidas 266 Vistas 0 Reseñas